Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2010

Open Access 01-12-2010 | Research

Downregulation of SPARC expression decreases gastric cancer cellular invasion and survival

Authors: Jie Yin, Guowei Chen, Yucun Liu, Si Liu, Pengyuan Wang, Yuanlian Wan, Xin Wang, Jing Zhu, Hongqiao Gao

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Login to get access

Abstract

Background

Secreted protein acidic and rich in cysteine (SPARC) plays a key role in the development of many tissues and organ types. Aberrant SPARC expression was found in a wide variety of human cancers, contributes to tumor development. Because SPARC was found to be overexpressed in human gastric cancer tissue, we therefore to explore the expression of SPARC in gastric cancer lines and the carcinogenic mechanisms.

Methods

SPARC expression was evaluated in a panel of human gastric cancer cell lines. MGC803 and HGC 27 gastric cancer cell lines expressing high level of SPARC were transiently transfected with SPARC-specific small interfering RNAs and subsequently evaluated for effects on invasion and proliferation.

Results

Small interfering RNA-mediated knockdown of SPARC in MGC803 and HGC 27 gastric cancer cells dramatically decreased their invasion. Knockdown of SPARC was also observed to significantly increase the apoptosis of MGC803 and HGC 27 gastric cancer cells compared with control transfected group.

Conclusions

Our data showed that downregulating of SPARC inhibits invasion and growth of human gastric cancer cells. Thus, targeting of SPARC could be an effective therapeutic approach against gastric cancer.
Appendix
Available only for authorised users
Literature
1.
International Agency for Research on Cancer (2004) Globocan 2002: Cancer Incidence, Mortality and Prevalence Worldwide, version 2.0. IARC CancerBase no. 5. Edited by: Ferlay J, Bray F, Pisani P, Parkin DM. Lyon, France: IARC Press
2.
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55 (2): 74-108. 10.3322/canjclin.55.2.74.CrossRef
3.
Wu Chun-xiao ZYBP: Pattern of changing incidence of gastric cancer and its time trend in Shanghai. 2008, 13: 24-29.
4.
Yan Q, Sage EH: SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem. 1999, 47 (12): 1495-1505.CrossRef
5.
Bradshaw AD, Sage EH: SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest. 2001, 107 (9): 1049-1054. 10.1172/JCI12939.CrossRef
6.
Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS: The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 2008, 27 (4): 691-705. 10.1007/s10555-008-9146-7.CrossRef
7.
Porter PL, Sage EH, Lane TF, Funk SE, Gown AM: Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem. 1995, 43 (8): 791-800.CrossRef
8.
Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL: Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res. 2000, 6 (3): 1140-1149.
9.
Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL: The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol. 1997, 108 (2): 210-214. 10.1111/1523-1747.ep12334263.CrossRef
10.
Rempel SA, Golembieski WA, Ge S, Lemke N, Elisevich K, Mikkelsen T, Gutierrez JA: SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J Neuropathol Exp Neurol. 1998, 57 (12): 1112-1121. 10.1097/00005072-199812000-00002.CrossRef
11.
Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, Mok SC: SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol. 2001, 159 (2): 609-622.CrossRef
12.
Yang EN, Kang HJ, Koh KH, Rhee H, Kim NK, Kim HG: Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer. 2007, 121 (3): 567-575. 10.1002/ijc.22706.CrossRef
13.
Puolakkainen PA, Brekken RA, Muneer S, Sage EH: Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res. 2004, 2 (4): 215-224.
14.
Chen G, Tian X, Liu Z, Zhou S, Schmidt B, Henne-Bruns D, Bachem M, Kornmann M: Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression. Br J Cancer. 2010, 102 (1): 188-195. 10.1038/sj.bjc.6605440.CrossRef
15.
DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC, Dahl GV: Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia. 2006, 20 (3): 426-432. 10.1038/sj.leu.2404102.CrossRef
16.
Wang CS, Lin KH, Chen SL, Chan YF, Hsueh S: Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Brit J Cancer. 2004, 91 (11): 1924-1930. 10.1038/sj.bjc.6602213.CrossRef
17.
Wewer UM, Albrechtsen R, Fisher LW, Young MF, Termine JD: Osteonectin/SPARC/BM-40 in human decidua and carcinoma, tissues characterized by de novo formation of basement membrane. Am J Pathol. 1988, 132 (2): 345-355.
18.
Maeng HY, Song SB, Choi DK, Kim KE, Jeong HY, Sakaki Y, Furihata C: Osteonectin-expressing cells in human stomach cancer and their possible clinical significance. Cancer Lett. 2002, 184 (1): 117-121. 10.1016/S0304-3835(02)00191-X.CrossRef
19.
Zhao ZS, Wang YY, Chu YQ, Ye ZY, Tao HQ: SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2010, 16 (1): 260-268. 10.1158/1078-0432.CCR-09-1247.CrossRef
20.
Franke K, Carl-McGrath S, Rohl FW, Lendeckel U, Ebert MP, Tanzer M, Pross M, Rocken C: Differential Expression of SPARC in Intestinal-type Gastric Cancer Correlates with Tumor Progression and Nodal Spread. Transl Oncol. 2009, 2 (4): 310-320.CrossRef
21.
Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y, Mordoh J, Podhajcer OL: Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med. 1997, 3 (2): 171-176. 10.1038/nm0297-171.CrossRef
22.
Maeng HY, Choi DK, Takeuchi M, Yamamoto M, Tominaga M, Tsukamoto T, Tatematsu M, Ito T, Sakaki Y, Furihata C: Appearance of osteonectin-expressing fibroblastic cells in early rat stomach carcinogenesis and stomach tumors induced with N-methyl-N '-nitro-N-nitrosoguanidine. Japanese Journal of Cancer Research. 2002, 93 (9): 960-967.CrossRef
23.
Inoue M, Senju S, Hirata S, Ikuta Y, Hayashida Y, Irie A, Harao M, Imai K, Tomita Y, Tsunoda T, Furukawa Y, Ito T, Nakamura Y, Baba H, Nishimura Y: Identification of SPARC as a candidate target antigen for immunotherapy of various cancers. Int J Cancer. 2010
24.
Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, Chambon P, Gespach C: Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer. 1995, 64 (1): 70-75. 10.1002/ijc.2910640114.CrossRef
25.
Tremble PM, Lane TF, Sage EH, Werb Z: SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J Cell Biol. 1993, 121 (6): 1433-1444. 10.1083/jcb.121.6.1433.CrossRef
26.
Rempel SA, Ge S, Gutierrez JA: SPARC: a potential diagnostic marker of invasive meningiomas. Clin Cancer Res. 1999, 5 (2): 237-241.
27.
Schittenhelm J, Mittelbronn M, Roser F, Tatagiba M, Mawrin C, Bornemann A: Patterns of SPARC expression and basement membrane intactness at the tumour-brain border of invasive meningiomas. Neuropathol Appl Neurobiol. 2006, 32 (5): 525-531. 10.1111/j.1365-2990.2006.00761.x.CrossRef
28.
Shi Q, Bao S, Song L, Wu Q, Bigner DD, Hjelmeland AB, Rich JN: Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene. 2007, 26 (28): 4084-4094. 10.1038/sj.onc.1210181.CrossRef
29.
Horie K, Tsuchihara M, Nakatsura T: Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction. Cancer Sci. 2009
30.
Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS, Bigner DD, Wang XF, Rich JN: Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem. 2004, 279 (50): 52200-52209. 10.1074/jbc.M409630200.CrossRef
31.
Said N, Najwer I, Motamed K: Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am J Pathol. 2007, 170 (3): 1054-1063. 10.2353/ajpath.2007.060903.CrossRef
32.
Tai IT, Dai M, Owen DA, Chen LB: Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest. 2005, 115 (6): 1492-1502. 10.1172/JCI23002.CrossRef
33.
Tai IT, Tang MJ: SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat. 2008, 11 (6): 231-246. 10.1016/j.drup.2008.08.005.CrossRef
34.
Iruela-Arispe ML, Lane TF, Redmond D, Reilly M, Bolender RP, Kavanagh TJ, Sage EH: Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo. Mol Biol Cell. 1995, 6 (3): 327-343.CrossRef
Metadata
Title
Downregulation of SPARC expression decreases gastric cancer cellular invasion and survival
Authors
Jie Yin
Guowei Chen
Yucun Liu
Si Liu
Pengyuan Wang
Yuanlian Wan
Xin Wang
Jing Zhu
Hongqiao Gao
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-29-59

Other articles of this Issue 1/2010

Journal of Experimental & Clinical Cancer Research 1/2010 Go to the issue

Research

The E-cadherin repressor slug and progression of human extrahepatic hilar cholangiocarcinoma

Research

Efficient inhibition of lung cancer in murine model by plasmid-encoding VEGF short hairpin RNA in combination with low-dose DDP

Research

Antisense oligonucleotide targeting Livin induces apoptosis of human bladder cancer cell via a mechanism involving caspase 3

Research

MicroRNAs involved in neoplastic transformation of liver cancer stem cells

Review

Current research in perineural invasion of cholangiocarcinoma

Review

Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug-induced apoptosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits